Unknown

Dataset Information

0

Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria.

ABSTRACT: Tafenoquine (an 8-aminoquinoline) was approved by the Food and Drug Administration (FDA) in 2018 for the radical cure of Plasmodium vivax malaria and preventive action against malaria. Despite the fact that the mechanism of action of the drug remains unclear, all studies indicated that a metabolite is responsible for its efficacy. Routes for the preparation of the drug are described.

SUBMITTER: Mayence A 

PROVIDER: S-EPMC6789594 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of <i>Plasmodium vivax</i> Malaria and Prophylaxis of Malaria.

Mayence Annie A   Vanden Eynde Jean Jacques JJ  

Pharmaceuticals (Basel, Switzerland) 20190730 3

Tafenoquine (an 8-aminoquinoline) was approved by the Food and Drug Administration (FDA) in 2018 for the radical cure of <i>Plasmodium vivax</i> malaria and preventive action against malaria. Despite the fact that the mechanism of action of the drug remains unclear, all studies indicated that a metabolite is responsible for its efficacy. Routes for the preparation of the drug are described. ...[more]

Similar Datasets

Unknown Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.
| S-EPMC5931686 | biostudies-literature
Unknown Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
| S-EPMC6657225 | biostudies-literature
Unknown Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
| S-EPMC6657226 | biostudies-literature
Unknown Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
| S-EPMC8094590 | biostudies-literature
Unknown Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria.
| S-EPMC7409770 | biostudies-literature
Unknown Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria.
| S-EPMC8427859 | biostudies-literature
Unknown How radical is radical cure? Site-specific biases in clinical trials underestimate the effect of radical cure on Plasmodium vivax hypnozoites.
| S-EPMC8686294 | biostudies-literature
Unknown Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.
| S-EPMC8168905 | biostudies-literature
Unknown Exposure-Response Analyses for Tafenoquine after Administration to Patients with Plasmodium vivax Malaria.
| S-EPMC4576039 | biostudies-literature
Unknown Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial.
| S-EPMC6753019 | biostudies-literature